



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

**MINUTES OF THE MEETING HELD ON WEDNESDAY 21<sup>st</sup> NOVEMBER 2018  
AT 12.30pm**

**IN SEMINAR ROOM 2, LEARNING & DEVELOPMENT CENTRE,  
ROYAL BLACKBURN HOSPITAL**

### **PRESENT:**

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr K Burch (KB)	Consultant Microbiologist ELHT

### **IN ATTENDANCE:**

Ms L Prince	Medicines Management Technician EL CCG
Ms N Everitt	Clinical Procurement Specialist Nurse (for item 2018/170)
Ms L Gawthrop	Integrated Wound Care Services (for item 2018/170)

### **2018/158: APOLOGIES:**

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr T Mckenzie (TM)	GP, EL CCG

### **2018/159: DECLARATION OF INTEREST**

None declared – relevant to agenda items.

### **2018/160: MINUTES OF OCTOBER MEETING:**

Accepted as a correct record.

### **2018/161: MATTERS ARISING:**

#### **2018/052: LMMG Recommendations (from Feb LMMG) - Melatonin guidelines –**

Awaiting LR/JV/CD to suggest updated wording to clarify point 3 on page 7 in the transition to adult services section. VG then to follow up with specialist.

**2018/073: Rifaxamin – Guidelines for Prescribing** – Awaiting JV/LR to amend document with information and then ask gastro pharmacist to review amended document against NICE.

**2018/135: Vitamin D Supplies for Paediatrics** – Hot Topic will be distributed this week.

**2018/149: LMMG Recommendations (from Sept LMMG) Anti-hyperglycaemic Guideline – updated** – comments have been sent to LMMG

**2018/149: LMMG Recommendations (from Sept LMMG) DMARD Shared Care Guideline** – template completed and shared. Accepted for in EL Health Economy.

**2018/151: ELHT: Procedure For The Administration Of Subcutaneous PRN Medication Using A Prescribed Range Of Doses For Symptoms In The Last Days Of Life** – comments incorporated and guidance accepted once author and review date added.

**2018/154: CCG Commissioning Policy For The Provision Of Continuous Glucose Monitoring And Flash Glucose Monitoring For Patients With Diabetes Mellitus** – comments from Dr Gardner fed back to LMMG and also to CCG policy group. CCG policy to remain as it is at present time. RMO North & South have slightly different policies which will be reviewed next year.

NF raised differences in parity across North West and expressed concerns re practicalities of dispensing. NF to raise at joint Chief Pharmacist/Heads MM meeting to review how other Trusts and localities were managing supplies.

#### **2018/162: NEW PRODUCT REQUEST – PLENVU® BOWEL CLEANSING AGENT**

Plenvu® requested by Dr J Collum, Consultant Gastroenterologist, for bowel cleansing prior to colonoscopy. Plenvu® is a lower volume preparation, with slightly higher costs, compared to other agents. ELMMB approved for use when a lower volume preparation would be beneficial.

**Resolved: Plenvu® approved for addition to formulary when a low volume preparation is required.**  
**Traffic Light: Red**

#### **2018/163: NEW PRODUCT REQUEST – DALBAVANCIN FOR INFUSION**

Dalbavancin requested by Dr K Burch, Consultant Microbiologist, for gram positive infections especially MRSA when oral treatment not appropriate and daily IV via OPAT is not feasible. It is administered either as a single IV dose of 1500mg or as 1000mg followed by 500mg one week later. The cost is over £1500 for the total course and would be for use on consultant microbiologist advice only, anticipated at 2-3 patients per year. Dalbavancin is approved for addition to formulary for use on consultant microbiology advice only.

**Resolved: Dalbavancin approved for addition to formulary on consultant microbiologist advice only.**  
**Traffic Light: Red**

## **2018/164: DRY EYE DROPS INCLUDING NEW PRODUCT REQUESTS – VISUXL®, SYSTANE BALANCE®, CLINITAS MULTI®**

VisuXL® for dry eye caused by poor epithelial healing, and Systane Balance® for evaporative dry eye, requested by Mr Usmani, Consultant Ophthalmologist. Clinitas multi® is suggested for inclusion by CCG. ELMMB was not convinced of the clinical effectiveness of the products presented and requested a more comprehensive review. It was suggested that the dry eye section of the Joint Formulary is reviewed to streamline the product choices; ensure the most cost effective products are included and ensure the Self Care Policy is referenced with respect to management of mild dry eyes. A number of current dry eye products were suggested for removal from formulary by ophthalmology.

**Action: Request further information on the product requests from ophthalmology.**

## **2018/170: WOUND CARE FORMULARY – COMPRESSION BANDAGE UPDATE**

Nicola Everitt & Lindsay Gawthrop in attendance for this item.

District nurses currently use 4 layer compression bandages which are currently on formulary. A proposal was made to switch to 2 layer bandages which are as effective, easier to apply, more comfortable for patients and require less DN time to change. Staff training is planned over the coming months with the intention to move over to 2 layer bandages for most patients. ELMMB approved addition of 2 layer compression bandages to wound care formulary.

**Resolved: Two layer compression bandages added to Wound Care formulary.**

## **2018/165: NEW PRODUCT REQUEST – ALICAFORSEN ENEMAS**

Alicaforsen Enemas (currently unlicensed) requested by Dr J Collum, for refractory pouchitis to be administered daily at home by the patient for 6 weeks with peak response at 10 weeks and remission potentially lasting 6 – 12 months. ELMMB agreed to support the request on an individual basis in exceptional cases. Once product becomes licensed a full evidence review will be required before being considered for inclusion on formulary.

**Resolved: Alicaforsen enemas to be considered in exceptional cases by the trust.**

## **2018/166: EMOLLIENTS REVIEW & RECOMMENDATIONS**

The summary of formulary changes for emollients were agreed at a meeting between all relevant parties. The prescribing guidelines have been approved by the dermatologists and the leaflets updated in line with new formulary choices.

Three of the heavy emollients are Amber to streamline initial choices for GP's and provide more cost effective options. Clinicians suggested removing all bath additives and patients referred to self-care. Patients would be consulted on the new choices.

**Resolved: Emollients on formulary to be updated in line with summary document. Prescribing Guidelines and updated leaflets approved.**

## **2018/167: LMMG CONSULTATIONS (for Dec LMMG)**

Concerns were expressed over the new mechanism for feeding back comments on LMMG consultations. The trust need to be aware of the comments that are being submitted as do the CCG. To be raised with LMMG.

**Hydroxychloroquine Prescriber Information Sheet** – no comments from ELMMB.

**Semaglutide Recommendation** – comment, do we need another product from this group.

**Xonvea® Recommendation** – suggested this should be green as most patients would present to primary care.

**Edoxaban first line Position Statement** – detailed comments sent to LMMG by cardiologist that the choice should not just be based on cost.

**Gout Prescribing Guidance** – comments from CCG been sent to LMMG

**Free of Charge Medicines Schemes: RMOG Guidance** – ELMMB support the guidance.

**Resolved: Comments to be sent to LMMG**

## **2018/167: LMMG RECOMMENDATIONS (from Oct LMMG)**

**Opicapone change from Black to Amber traffic light recommended** – accepted for use in ELHE. **Traffic Light: Amber**

**Actipatch Recommendation** – not recommended for use. Accepted as written for use in ELHE. **Traffic light: Black**

**Headache Management Pathway** – Box 1 should not state 'acute interventions'. LR to feedback to LMMG.

## **2018/169: FORMULARY UPDATES**

**Adcal D3** – defer to next meeting

**VSL#3 Sachets** – remove from formulary as these have been taken out of drug tariff and are no longer able to be prescribed.

**Latanoprost/Timolol eye drops** – add to formulary as green as cost effective option for combined product. **Traffic Light: Green**

**Levosert® IUD (levonorgestrel)** – A number of questions were raised over potential advantages this product offered over Mirena. Other issues raised included the need for training and education and updates to PGDs. Item was deferred to next meeting for more information and in depth discussion.

**Resolved: Formulary to be updated as above**

## **2018/171: OVERACTIVE BLADDER SYNDROME GUIDELINE - UPDATED**

Layout has been updated and oxybutin IR removed. Request to include generic name for oxybutynin MR and move solifenacin from the top of the list. Approved for upload to website when amendments completed.

**Resolved: Updated Overactive Bladder Syndrome Guideline approved when amendments completed.**

## **2018/172: TREND DIABETES LEAFLETS**

Leaflets shared as useful resources for diabetic patients. Upload to website for information.

**Resolved: TREND diabetes leaflets to be uploaded to website.**

## **2018/173: CCG ADRENALINE PROTOCOL**

Adrenaline protocol for use by CCG's acknowledged.

**Resolved: CCG Adrenaline Protocol acknowledged.**

## **2018/174: CANNABIS BASED PRODUCTS FOR MEDICINAL USE**

Information for awareness. LMMG will be issuing a statement for consultation next month.

**Resolved: Information for awareness acknowledged.**

## **2018/175: NICE RECOMMENDATIONS (from Oct)**

Cabozantinib for untreated advanced renal cell carcinoma [TA542] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [TA543] is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned – Blueteq form required

**Traffic Light: RED**

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293 updated) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned – Blueteq form required

**Traffic Light: RED**

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221 updated) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned – Blueteq form required

**Traffic Light: RED**

## **STANDING ITEMS**

### **2018/176: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Oct 2018**

Minutes acknowledged

### **2018/177: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Sept 2018**

Minutes acknowledged

## **High Potency Opiates**

VG stated we need a leaflet for patients starting high potency opiates, to be in line with NICE recommendations. A leaflet from Wales is being considered in consultation with chronic pain with a view to adopting it. Leaflet will be brought to ELMMB when ready.

**DATE OF NEXT MEETING – Wednesday 19<sup>th</sup> December 2018 12.30pm, Pharmacy Seminar Room, Pharmacy Department, RBH.**

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 21<sup>ST</sup> NOVEMBER 2018**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2018/052</b>	<b>LMMG Recommendations (from Feb LMMG) Melatonin guidelines –</b> suggest wording to clarify transitional information. Follow up with specialists	LR/JV/CD	Nov 18
		VG	Nov 18
<b>2018/073</b>	<b>Rifaxamin – Guidelines for Prescribing</b> –amend document with comments. Gastro pharmacist review against NICE	LR/JV	Nov 18
		VG	Nov 18
<b>2018/164</b>	<b>Dry Eye Drops Including New Product Requests – VisuXl®, Systane Balance®, Clinitas Multi®</b> - request further information from ophthalmology and discuss.	CW	Dec 18 / Jan 19
<b>2018/167</b>	<b>LMMG Recommendations (from Oct LMMG) – Headache Management Pathway</b> – feedback comment for Box 1	LR	Dec 18
<b>2018/169</b>	<b>Formulary Updates: Levosert® IUD (levonorgestrel)</b> – further information to be obtained	CW	Dec 18